🇺🇸 FDA
Pipeline program

REGN7508

R7508-DVT-24120

Phase 3 small_molecule active

Quick answer

REGN7508 for Symptomatic Venous Thromboembolism (VTE) is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Symptomatic Venous Thromboembolism (VTE)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials